Figure 3.

OVA-Texo counteracts CD8⁺ T-cell anergy via CD40L signaling. AdV_Gal-infected C57BL/6 mice were immunized with (a) the OVA-Texo vaccine or the OVA-Texo vaccine deficient for one of several molecules or (b) the OVA-Texo vaccine plus anti-CD40L antibody treatment. Six days after the immunization, mouse peripheral blood samples were stained with PE-tetramer and FITC-CD8, and analyzed for the assessment of OVA-specific CTLs by flow cytometry. The value in each panel represents the percentage of PE-tetramer-positive CD8⁺ T cells in the total peripheral CD8⁺ T-cell population. *P<0.05, **P<0.01. Error bars represent the s.d. One representative experiment of two is shown.